1. Home
  2. CRBP vs MFM Comparison

CRBP vs MFM Comparison

Compare CRBP & MFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRBP

Corbus Pharmaceuticals Holdings Inc.

N/A

Current Price

$5.42

Market Cap

190.3M

Sector

Health Care

ML Signal

N/A

Logo MFS Municipal Income Trust

MFM

MFS Municipal Income Trust

N/A

Current Price

$4.95

Market Cap

224.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CRBP
MFM
Founded
2009
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
224.5M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
CRBP
MFM
Price
$5.42
$4.95
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
★ $34.03
N/A
AVG Volume (30 Days)
★ 1.1M
642.4K
Earning Date
11-11-2026
01-01-0001
Dividend Yield
N/A
★ 4.08%
EPS Growth
N/A
★ N/A
EPS
N/A
★ 0.03
Revenue
★ $4,822,272.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$116.00
N/A
P/E Ratio
★ N/A
$164.33
Revenue Growth
★ 97.62
N/A
52 Week Low
$5.13
$4.75
52 Week High
$20.56
$5.67

Technical Indicators

Market Signals
Indicator
CRBP
MFM
Relative Strength Index (RSI) 23.84 43.70
Support Level N/A N/A
Resistance Level $8.13 $5.53
Average True Range (ATR) 0.42 0.11
MACD -0.10 0.01
Stochastic Oscillator 10.17 52.70

Price Performance

Historical Comparison
CRBP
MFM

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About MFM MFS Municipal Income Trust

MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.

Share on Social Networks: